

# American Life Science Pharmaceuticals (ALSP) – Executive Summary

ALSP Inc.

7514 Girard Ave., Ste. 1-301  
La Jolla CA 92037-5199

## Management Team

### J. Steven Jacobsen, Ph.D.

CEO and CSO

Formerly with Wyeth/Pfizer, Proteostasis Therapeutics, AstraZeneca

### Michael D. Pierschbacher, Ph.D.

President

Formerly SVP Integra Life Sciences; founder Telios Pharma; La Jolla Cancer Res Foundation

### Greg Hook, Ph.D., J.D.

VP Research and General Counsel

Formerly patent attorney Campbell & Flores; Patent Examiner USPTO; scientist NIH

### Dallas Hack, M.D.

Medical Affairs

Colonel, US Army (retired); former Director, Combat Casualty Care Research Program

## Board of Directors

### J. Gregory Swendsen, Chairman

### J. Steven Jacobsen, Ph.D.

### Michael D. Pierschbacher, Ph.D.

### Greg Hook, Ph.D., J.D.

### Bernice Welles, M.D., M.B.A.

## Scientific Advisory Board

### Vivian Hook\*, Ph.D., UCSD

### Greg Hook\*, Ph.D.

### Ken Grabstein, Ph.D., U of Wash

### Dallas Hack, M.D.

### J. Steven Jacobsen, Ph.D.

\*Co-founders

## CHALLENGE: TBI – A GROWING UNMET MEDICAL NEED

- Traumatic brain injury (TBI) is a neurodegenerative disease (NDD) that is devastating to patients, caregivers, families and healthcare systems
- Estimated 2.8M Americans seek emergency room assistance each year
- There are no FDA approved drugs for TBI and this constitutes a national healthcare priority; potential fast-track status will expedite approval

## BUSINESS OPPORTUNITY

- **About us:** ALSP is a biotherapeutic company that has developed a small molecule treatment for neurological diseases with unmet medical needs
- **Approach:** To reduce activation of the NLRP3 inflammasome, a key driver of neuroinflammation and pathology, which is common to several neurological diseases
- **Objective:** To rapidly demonstrate clinical proof-of-principle for the treatment of traumatic brain injury (TBI), an acute brain injury (ABI)
- **Market potential:** TBI disease-modifying treatment is expected to yield total annual revenues in excess of of \$1B in 3 years and \$4B in 7 years
- **Future:** Expansion of the platform for the treatment of additional ABIs (stroke & spinal cord injury) and NDDs, such as Alzheimer's and Parkinson's Disease, will provide additional blockbuster market potential

## NOVEL APPROACH FOR TREATING TBI

- Published genetic and pharmacological data demonstrating NLRP3 activation in preclinical models of ABIs and NDDs; inhibition is efficacious
- Published data link Cathepsin B with NLRP3 activation; reduction or inhibition of Cathepsin B *in vivo* is efficacious in preclinical models
- ALSP published genetic and pharmacological data demonstrating small molecule inhibition of Cathepsin B is efficacious in TBI model
- ALSP published a unique broad window for therapeutic intervention following TBI is neuroprotective and sustains function

## PROPRIETARY POSITION

- Issued patents in US (compounds, compositions and formulations) and EU (compounds and medicaments)
- Additional claims pending for ongoing expansion of patent estate to reinforce IP strategy

## ASK TO INVESTORS

- **Program status:** Proprietary clinical candidate in early stage Discovery
- **Initial financing:** Request of \$3M for milestone driven completion of Discovery activities including: synthesis, PK profiling, selectivity, target engagement, biomarker assessment and efficacy in preclinical models
- **Subsequent financing:** Request of \$7M for non-clinical assessment of synthesis, formulation and toxicology assessment for IND submission